Sonidegib (Odomzo®), an FDA-approved oral, selective smoothened (SMO) inhibitor used to treat basal cell carcinomas via regulation of the hedgehog (Hh) signaling pathway [103,104,105] was among the best drug candidates predicted to impede the formation of the obligatory nsp16/nsp10 complex by stably occupying the nsp16 activating surface. Here, SMO is linked to basal cell carcinoma.